MedPath

Effect of Iron-fortified Pea Powder on Exercise Performance

Not Applicable
Completed
Conditions
Iron-deficiency
Interventions
Dietary Supplement: Placebo (maltodextrin)
Dietary Supplement: Regular pea powder
Dietary Supplement: Low phytate pea powder
Registration Number
NCT04872140
Lead Sponsor
University of Saskatchewan
Brief Summary

Female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. This study assesses the impact of an pea protein supplement with high iron bio-availability on iron status and exercise performance.

Detailed Description

Female endurance athletes are susceptible to iron deficiency due to poor iron intake from diets or possibly because of destruction of red blood cells during foot-strike hemolysis. This study will evaluate the impact of 8-weeks of iron supplementation through consumption of a pea-protein power that has high iron bio-availability due to low phytate levels. This will be compared to consumption of regular iron protein powder and maltodextrin placebo by randomizing participants to three groups. Participants will be assessed at baseline and after 8 weeks of supplementation for exercise performance (maximal aerobic capacity and a 5 km time trial running test), blood levels of ferritin and hemoglobin, and body composition (fat mass and lean tissue mass).

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
28
Inclusion Criteria
  • Female
  • Regularly participate in aerobic endurance training
Exclusion Criteria
  • Any contra-indications to exercise testing as determined with the "Get Active Questionnaire"

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo (maltodextrin)Placebo (maltodextrin) powder (0g iron per day)
Pea powderRegular pea powderPea powder with normal phytate levels (7mg iron per day)
Pea power with high iron bio-availabilityLow phytate pea powderPea powder with low phytate levels to increase iron bio-availability (7mg iron per day)
Primary Outcome Measures
NameTimeMethod
Change from baseline in ferritin levelsUp to 8 weeks

blood ferritin levels

Secondary Outcome Measures
NameTimeMethod
Change from baseline in hemoglobin levelsUp to 8 weeks

Blood hemoglobin concentration

Change from baseline in lean tissue massUp to 8 weeks

Lean tissue mass (kg) measured with dual energy X-ray absorptiometry

Change from baseline in maximal aerobic capacityUp to 8 weeks

Maximal aerobic capacity (mL/kg/min) measured on a treadmill

Change from baseline in exercise time trial performanceUp to 8 weeks

Time (minutes) to complete 5 km running on a treadmill

Change from baseline in fat massUp to 8 weeks

Fat mass (kg) measured with dual energy X-ray absorptiometry

Trial Locations

Locations (1)

University of Saskatchewan

🇨🇦

Saskatoon, Saskatchewan, Canada

© Copyright 2025. All Rights Reserved by MedPath